{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:56:02Z","timestamp":1791510962241,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Characterizing trends in mortality rates with consideration of trends in incidence rates at the population level could help identify unmet needs in public health and provide essential indicators of cancer control. In the late 20th century, the arrival of the first molecular targeted agent, rituximab, for non\u2010Hodgkin lymphoma (NHL) led to a paradigm shift in NHL treatment. However, the public health impact of this arrival has not been fully clarified. Here, we evaluated trends in the mortality and incidence rates of NHL in Japan and the United States. Age\u2010standardized rates of mortality reversed after the introduction of rituximab, around 2000, beginning to decline significantly with annual percent changes (95% confidence interval) of \u22122.6% (\u22123.6% to \u22121.6%) in Japan and\u2009\u2212\u20093.9% (\u22124.2% to \u22123.5%) in the United States. Despite an increase in incidence, the mortality in all age groups weakened the upward trends or decreased in both countries. From a long\u2010term perspective, the trends in mortality rates differed between the countries. In the United States, the mortality rate has declined continuously since the introduction of rituximab, with a declining incidence rate. In contrast, in Japan, the mortality rate stopped declining and the incidence rate increased remarkably. The introduction of rituximab has had a substantial impact at the population level across a wide range of individuals. To reduce the disease burden in terms of mortality, elucidating risk factors that lead to a decreasing incidence rate is warranted for NHL, as well as further development of novel treatments.<\/jats:p>","DOI":"10.1111\/cas.15926","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T17:53:04Z","timestamp":1692640384000},"page":"4073-4080","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trends in non\u2010Hodgkin lymphoma mortality rate in Japan and the United States: A population\u2010based study"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-0704","authenticated-orcid":false,"given":"Yoshiaki","family":"Usui","sequence":"first","affiliation":[{"name":"Division of Cancer Information and Control, Department of Preventive Medicine Aichi Cancer Center  Nagoya Japan"},{"name":"Department of Hematology, Oncology and Respiratory Medicine Okayama University Medical School  Okayama Japan"},{"name":"Laboratory for Genotyping Development RIKEN Center for Integrative Medical Sciences  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-4581","authenticated-orcid":false,"given":"Hidemi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Cancer Information and Control, Department of Preventive Medicine Aichi Cancer Center  Nagoya Japan"},{"name":"Division of Descriptive Cancer Epidemiology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Katanoda","sequence":"additional","affiliation":[{"name":"Division of Cancer Statistics Integration Center for Cancer Control and Information Services, National Cancer Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-1233","authenticated-orcid":false,"given":"Tomohiro","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Division of International Health Policy Research Institute for Cancer Control, National Cancer Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceuticals Sciences  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1761-6314","authenticated-orcid":false,"given":"Keitaro","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine Aichi Cancer Center  Nagoya Japan"},{"name":"Department of Epidemiology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28990"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.22.2975"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1905447"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6611"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33135"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0197"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708875"},{"key":"e_1_2_11_10_1","unstructured":"List of approved drug products.Pharmaceuticals and Medical Devices Agency. Accessed December 13 2019.https:\/\/www.pmda.go.jp\/review\u2010services\/drug\u2010reviews\/review\u2010information\/p\u2010drugs\/0010.html"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf155"},{"key":"e_1_2_11_12_1","unstructured":"Drugs@FDA: FDA Approved Drug Products.U.S. Food & Drug Administration. Accessed December 13 2019.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09177.x"},{"key":"e_1_2_11_17_1","first-page":"5117","article-title":"Survival in advanced diffuse large B\u2010cell lymphoma in pre\u2010 and post\u2010rituximab Eras in the United States","volume":"34","author":"Shah BK","year":"2014","journal-title":"Anticancer Res"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251"},{"key":"e_1_2_11_19_1","unstructured":"National Cancer Institute. Surveillance E and End Results.U.S. Mortality\u2010All COD Aggregated Total U.S. (1969\u20132015) <Katrina\/Rita Adjustment>. Accessed December 13 2019. Available at SEER*Stat Software."},{"key":"e_1_2_11_20_1","unstructured":"National Cancer Institute. Surveillance E and End Results.SEER Cause of Death Recode 1969+ (03\/01\/2018). Accessed December 13 2019.https:\/\/seer.cancer.gov\/"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv088"},{"key":"e_1_2_11_22_1","unstructured":"National Cancer Institute. Surveillance E and End Results.U.S.Incidence\u2010SEER18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases Nov 2017 Sub [1973\u20132015 varying]. Accessed December 13 2019. Available at SEER*Stat Software."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-016-0790-x"},{"key":"e_1_2_11_24_1","unstructured":"Cancer Registry and Statistics.Cancer Information Service National Cancer Center Japan (Ministry of Health Labour and Welfare National Cancer Registry). Accessed December 13 2019.https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html"},{"key":"e_1_2_11_25_1","unstructured":"National Cancer Institute. Surveillance E and End Results.U.S. Population\u2010Total U.S. (1969\u20132015) <Katrina\/Rita Adjustment>. Accessed December 13 2019. Available at SEER*Stat Software."},{"key":"e_1_2_11_26_1","unstructured":"National Cancer Institute.Surveillance E and End Result. Standard Population Data World (WHO 2000\u20132025) Standard. Accessed December 13 2019.https:\/\/seer.cancer.gov\/"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3733"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7257.323"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T19:23:04Z","timestamp":1696533784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.15926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/cas.15926"],"URL":"https:\/\/doi.org\/10.1111\/cas.15926","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"2023-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}